NCT06587867View on ClinicalTrials.gov

Seronegative Myasthenia Gravis - Efgartigimod IV

PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
EfgartigimodGeneralized Myasthenia Gravis
Interventions
BIOLOGICAL

efgartigimod

active drug efgartigimod to be administer

Trial Locations (1)

M5G 2C4

RECRUITING

University Health Network, Division of Neurology, Toronto General Hospital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER